Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients

Findings from CALGB 89803 and CALGB 80405

Katherine Van Loon, Devin Wigler, Donna Niedzwiecki, Alan P. Venook, Charles Fuchs, Charles Blanke, Leonard Saltz, Richard M. Goldberg, Jeffrey A. Meyerhardt

Research output: Contribution to journalArticle

12 Citations (Scopus)

Abstract

Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.

Original languageEnglish (US)
Pages (from-to)95-102
Number of pages8
JournalClinical Colorectal Cancer
Volume12
Issue number2
DOIs
StatePublished - 2013
Externally publishedYes

Fingerprint

Feeding Behavior
Life Style
Colorectal Neoplasms
Colon
Metabolic Equivalent
Drug Therapy
Recommended Dietary Allowances
National Cancer Institute (U.S.)
Vitamin D
Tobacco Products
Vegetables
Colonic Neoplasms
Fruit
Milk
Body Mass Index

Keywords

  • Behavioral patterns
  • Chemotherapy
  • Colon cancer
  • Exercise
  • Nutrition

ASJC Scopus subject areas

  • Oncology
  • Gastroenterology

Cite this

Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients : Findings from CALGB 89803 and CALGB 80405. / Van Loon, Katherine; Wigler, Devin; Niedzwiecki, Donna; Venook, Alan P.; Fuchs, Charles; Blanke, Charles; Saltz, Leonard; Goldberg, Richard M.; Meyerhardt, Jeffrey A.

In: Clinical Colorectal Cancer, Vol. 12, No. 2, 2013, p. 95-102.

Research output: Contribution to journalArticle

Van Loon, Katherine ; Wigler, Devin ; Niedzwiecki, Donna ; Venook, Alan P. ; Fuchs, Charles ; Blanke, Charles ; Saltz, Leonard ; Goldberg, Richard M. ; Meyerhardt, Jeffrey A. / Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients : Findings from CALGB 89803 and CALGB 80405. In: Clinical Colorectal Cancer. 2013 ; Vol. 12, No. 2. pp. 95-102.
@article{a2546556184e423c851c2f80b78f344e,
title = "Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients: Findings from CALGB 89803 and CALGB 80405",
abstract = "Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9{\%} of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47{\%} of stage III and 43{\%} of metastatic patients. Dietary patterns for both groups were comparable with more than 80{\%} of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49{\%} of stage III and 40{\%} of metastatic patients. Two percent of stage III and 5{\%} of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.",
keywords = "Behavioral patterns, Chemotherapy, Colon cancer, Exercise, Nutrition",
author = "{Van Loon}, Katherine and Devin Wigler and Donna Niedzwiecki and Venook, {Alan P.} and Charles Fuchs and Charles Blanke and Leonard Saltz and Goldberg, {Richard M.} and Meyerhardt, {Jeffrey A.}",
year = "2013",
doi = "10.1016/j.clcc.2012.11.002",
language = "English (US)",
volume = "12",
pages = "95--102",
journal = "Clinical Colorectal Cancer",
issn = "1533-0028",
publisher = "Elsevier",
number = "2",

}

TY - JOUR

T1 - Comparison of dietary and lifestyle habits among stage III and metastatic colorectal cancer patients

T2 - Findings from CALGB 89803 and CALGB 80405

AU - Van Loon, Katherine

AU - Wigler, Devin

AU - Niedzwiecki, Donna

AU - Venook, Alan P.

AU - Fuchs, Charles

AU - Blanke, Charles

AU - Saltz, Leonard

AU - Goldberg, Richard M.

AU - Meyerhardt, Jeffrey A.

PY - 2013

Y1 - 2013

N2 - Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.

AB - Background: Cancer patients often pursue lifestyle and dietary changes with the aim to improve outcomes. Using data from 2 large National Cancer Institute-sponsored clinical trials, we report on the dietary and lifestyle practices of patients receiving therapy for stage III colon or metastatic colorectal cancer. Patients and Methods: Self-administered questionnaires were completed by patients undergoing chemotherapy for stage III colon cancer (n = 1095) and metastatic colorectal cancer (n = 875). Descriptive statistical analyses were performed to evaluate anthropometrics, diet, and lifestyle in each cohort. Results: Median body mass index was comparable for stage III and metastatic patients (27.3 vs. 26.5 kg/m2). Stage III patients reported a modestly higher median level of physical activity than metastatic patients (4.6 vs. 3.4 metabolic equivalent task-hours per week). Ten percent of stage III and 9% of metastatic patients reported ongoing cigarette use. Avoidance of alcohol was reported by 47% of stage III and 43% of metastatic patients. Dietary patterns for both groups were comparable with more than 80% of stage III and metastatic patients failing to meet the recommended daily intake of vegetables, fruits, and milk products. Usage of at least 2 multivitamins per week was reported by 49% of stage III and 40% of metastatic patients. Two percent of stage III and 5% of metastatic patients reported vitamin D supplement use. Conclusions: We observed notable similarities in dietary and lifestyle behaviors between stage III colon and metastatic colorectal cancer patients actively receiving chemotherapy. Future research should aim to elucidate the effect of these behaviors on patient outcomes.

KW - Behavioral patterns

KW - Chemotherapy

KW - Colon cancer

KW - Exercise

KW - Nutrition

UR - http://www.scopus.com/inward/record.url?scp=84876842184&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876842184&partnerID=8YFLogxK

U2 - 10.1016/j.clcc.2012.11.002

DO - 10.1016/j.clcc.2012.11.002

M3 - Article

VL - 12

SP - 95

EP - 102

JO - Clinical Colorectal Cancer

JF - Clinical Colorectal Cancer

SN - 1533-0028

IS - 2

ER -